#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic myeloid leukaemia (in remission) Osteopetrosis Synovial sarcoma Malignant central nervous system neoplasm B-cell small lymphocytic lymphoma refractory Crohn's disease Acute graft versus host disease in intestine Hormone-dependent prostate cancer Autologous haematopoietic stem cell transplant ABO haemolytic disease of newborn Anti-glomerular basement membrane disease MELAS syndrome Myelodysplastic syndrome with excess blasts Familial hypertriglyceridaemia Measles More trials…

    Learn about Rare Diseases

    Lymphangioma – Trials in Disease Lymphangioma – Diagnostics Andersen-Tawil syndrome Pleural mesothelioma malignant – Trials in Disease Glycogen storage disease type II – Trials in Disease Prolymphocytic leukaemia – Basic Information Hereditary optic atrophy – Basic Information Hairy cell leukaemia – Treatment Glomerulonephritis rapidly progressive – Treatment Hepatoblastoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Thiamine Hydrochloride C1 Esterase Inhibitor (Human) Vepdegestrant Resiquimod Sulfate TETRODOTOXIN Recombinant Interferon Beta-1B TTX-381 Pabinafusp Alfa Azd5004 AP31969 SULFATE Imipenem Mcla-129 Mps-214 Gfh925 Pazopanib Benzylpenicillin Keto-Leucine Calcium Argon Enomimeran Betamethasone Dipropionate More therapies…

    Learn about Your Condition

    Indolent systemic mastocytosis Developmental hip dysplasia Haemorrhagic stroke Hyponatraemia Lung neoplasm malignant Laryngeal cancer stage II Synovial sarcoma metastatic Anal cancer stage II Haemophilia Testicular leiomyosarcoma Stress urinary incontinence Diabetic nephropathy Acute myeloid leukaemia Microscopic polyangiitis Gaucher's disease type III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Nodal marginal zone B-cell lymphoma

  • Epcoritamab for Adults with Relapsed or Refractory Marginal Zone Lymphoma: A Phase II Open‑Label Study

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Extranodal marginal zone B-cell lymphoma (MALT type)
    • Splenic marginal zone lymphoma
    • Nodal marginal zone B-cell lymphoma
    Investigated Drugs:
    • Epcoritamab
    Germany

  • Study of Obinutuzumab as First-Line Treatment for Adult Patients with Marginal Zone Lymphoma Who Are Not Eligible for Local Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Extranodal marginal zone B-cell lymphoma (MALT type)
    • Splenic marginal zone lymphoma
    • Nodal marginal zone B-cell lymphoma
    Investigated Drugs:
    • Obinutuzumab
    Germany

  • Study on Copanlisib and Rituximab for Patients with Marginal Zone Lymphoma Needing Treatment After Local Therapy Failure or Relapse

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Extranodal marginal zone B-cell lymphoma (MALT type)
    • Splenic marginal zone lymphoma
    • Nodal marginal zone B-cell lymphoma
    Investigated Drugs:
    • Copanlisib Dihydrochloride
    • Rituximab
    Germany

  • Study on Lisocabtagene Maraleucel for Adults with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • B-cell lymphoma
    Investigated Drugs:
    • Lisocabtagene Maraleucel
    Austria France Germany Italy Spain Sweden

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!